Canagliflozin, the first SGLT2 inhibitor approved by the U.S. Food and Drug Administration (FDA) in March 2013, improved glycaemic control in individuals with type 2 diabetes over a 26-week period 7. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.